The world’s largest pharmaceutical companies are reportedly calling upon the US to protect their intellectual property as emerging markets are looking to bring down healthcare costs through generic drugs.
Sources say India’s government is looking into breaking pharmaceuticals’ exclusivity rights through compulsory licenses, allowing the government to launch generic and cheaper forms of the treatments. Those same sources say the drugs involved in the review include cancer, diabetes, HIV and hepatitis treatments, though the pharmaceutical firms that could be effected were not specified.
Major drug makers including Pfizer, Novartis, Roche Holding and Sanofi reportedly hold a major market share in India.
Reports say India is already being closely monitored by regulators and is listed on the US Priority Watch List, which pinpoints nations whose intellectual property policies should be watched.
According to one source in New Delhi who reports say is “directly involved” with the matter, “the multinational companies are exploring all options – from paring their investments in the country to forcing the US to take some actions.”
Other nations on the US Priority Watch List include Argentina, Pakistan, Russia and China.
Earlier this month South Africa was reported to be an emerging epicenter of the tension between generic and brand name pharmaceuticals as it, too, is considering government policies that would allow the release of generic forms of drugs before patents for brand names expire.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI